Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood

Future Science OA

Volumn 1, Issue 3, 2015, Pages

  Qu, Ying ^a   Noe, Gaelle ^b   Breaud, Autumn R ^c   Vidal, Michel ^b,d   Clarke, William A ^c   Zahr, Noel ^e   Dervieux, Thierry ^a   Costedoat Chalumeau, Nathalie ^b,f   Blanchet, Benoit ^b  

^a United Rheumatology   (United States)

^b APHP ^*  (France)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d CNRS   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

clinical drug monitoring; desethylchloroquine; desethylhydroxychloroquine; drug monitoring; fluorescence detection; HPLC; hydroxychloroquine; LC MS MS; systemic lupus erythematosus; whole blood

Indexed keywords

CELECOXIB; CHLOROQUINE; DEETHYLCHLOROQUINE; DESETHYLHYDROXYCHLOROQUINE; DRUG METABOLITE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PRODUCT RECOVERY; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION PROCESS;

EID: 85017155776     PISSN: None     EISSN: 20565623     Source Type: Journal    
DOI: 10.4155/fso.15.24     Document Type: Article

References (24)

1. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. 324(3), 150-154 (1991).
2. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin. Arthritis Rheum. 43(2), 264-272 (2013).
3. Costedoat-Chalumeau N, Dunogue B, Morel N, Le G V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 43(6 Pt 2), e167-e180 (2014).
4. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 64(12), 4021-4028 (2012).
5. Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J. Rheumatol. 40(6), 831-841 (2013).
6. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15(9), 577-583 (2006).
7. Alarcon GS, McGwin G, Bertoli AM et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66(9), 1168-1172 (2007).
8. Shinjo SK, Bonfa E, Wojdyla D et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 62(3), 855-862 (2010).
9. Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol. 49(6), 549-554 (2000).
10. Davila L, Ranganathan P. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat. Rev. Rheumatol. 7(9), 537-550 (2011).
11. Brocks DR, Skeith KJ, Johnston C et al. Hematologic disposition of hydroxychloroquine enantiomers. J. Clin. Pharmacol. 34(11), 1088-1097 (1994).
12. Munster T, Gibbs JP, Shen D et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 46(6), 1460-1469 (2002).
13. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54(10), 3284-3290 (2006).
14. Costedoat-Chalumeau N, Amoura Z, Hulot JS et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 66(6), 821-824 (2007).
15. Tett SE, Cutler DJ, Brown KF. High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly (styrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection. J. Chromatogr. 344, 241-248 (1985).
16. Tett SE, Cutler DJ, Beck C, Day RO. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis-a prospective, dose ranging study. J. Rheumatol. 27(7), 1656-1660 (2000).
17. Costedoat-Chalumeau N, Galicier L, Aumaitre O et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann. Rheum. Dis. 72(11), 1786-92 (2013).
18. Williams SB, Patchen LC, Churchill FC. Analysis of blood and urine samples for hydroxychloroquine and three major metabolites by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 433, 197-206 (1988).
19. Wang LZ, Ong RY, Chin TM et al. Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 61, 86-92 (2012).
20. Fuzery AK, Breaud AR, Emezienna N, Schools S, Clarke WA. A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry. Clin. Chim. Acta 421, 79-84 (2013).
21. Soichot M, Megarbane B, Houze P et al. Development, validation and clinical application of a LC-MS/MS method for the simultaneous quantification of hydroxychloroquine and its active metabolites in human whole blood. J. Pharm. Biomed. Anal. 100, 131-137 (2014).
22. FDA, U. S. Department of Health and Human Services Center for Drug Evaluation and Research CDER Center for Veterinary Medicine CVM. Guidance for Industry www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf
23. Passing H, Bablok W. Comparison of several regression procedures for method comparison studies and determination of sample sizes. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part II. J. Clin. Chem. Clin. Biochem. 22(6), 431-445 (1984).
24. Bland JM, Altman DJ. Regression analysis. Lancet 1(8486), 908-909 (1986).